Treatment of retinal vasculitis in Behçt's disease with rituximab

Modern Rheumatology

Volumn 18, Issue 3, 2008, Pages 306-308

  Sadreddini, Shahram ^a   Noshad, Hamid ^a   Molaeefard, Mahshid ^b   Noshad, Rahim ^a  

^a TABRIZ UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

Beh et's disease; Retinal vasculitis; Rituximab

Indexed keywords

AZATHIOPRINE; C REACTIVE PROTEIN; CD20 ANTIGEN; CORTICOSTEROID; CREATININE; ETANERCEPT; HEMOGLOBIN; IMMUNOGLOBULIN A; IMMUNOGLOBULIN G; METHYLPREDNISOLONE; MYDRIATIC AGENT; NITROGEN; PREDNISOLONE; RITUXIMAB; STEROID; UREA;

ABSENCE OF SIDE EFFECTS; ADULT; ANEMIA; ANGIONEUROTIC EDEMA; APHTHOUS ULCER; ARTHRALGIA; ARTICLE; AUTOIMMUNITY; B LYMPHOCYTE; BEHCET DISEASE; CASE REPORT; CHRONIC KIDNEY FAILURE; CLINICAL EXAMINATION; CLINICAL FEATURE; DRUG DOSE REDUCTION; ERYTHROCYTE SEDIMENTATION RATE; FEVER; FOLLOW UP; GENITAL ULCER; HOSPITAL ADMISSION; HUMAN; INFORMED CONSENT; IRAN; LYMPHOCYTOPENIA; MALE; MEDICAL DECISION MAKING; MOUTH ULCER; OUTCOME ASSESSMENT; PRIORITY JOURNAL; RASH; REMISSION; RETINA VASCULITIS; T LYMPHOCYTE; TEACHING HOSPITAL; TREATMENT OUTCOME; UREA NITROGEN BLOOD LEVEL; URTICARIA; VISUAL ACUITY; VISUAL IMPAIRMENT; VISUAL SYSTEM EXAMINATION;

ADULT; ANTIBODIES, MONOCLONAL; ANTIRHEUMATIC AGENTS; BEHCET SYNDROME; HUMANS; MALE; REMISSION INDUCTION; RETINAL VASCULITIS;

EID: 46549090127     PISSN: 14397595     EISSN: 14397609     Source Type: Journal    
DOI: 10.1007/s10165-008-0057-9     Document Type: Article

References (12)

1. Porter SR, Al-Otaibi LM, Poate TWJ. Behçet's disease: A review. J Dent Res. 2005;84:209-22.
2. Kansu T, Kadayifcilar S. Visual aspects of Behçet's disease. Curr Treat Options Neurol. 2007;8:81-8.
3. Stashenko P, Nadler LM, Hardy R, Schlossman SF. Characterization of a human B lymphocyte-specific antigen. J Immunol. 1980;125:1678-85.
4. Davachi F. New and innovative therapies for Behçet's disease. APLAR J Rheum. 2004;7:141-5.
5. Kneitz C, Wilhelm M, Tony H. Effective B cell depletion with rituximab in treatment of autoimmune diseases. J Immunobiol. 2002;206:519-27.
6. Smith MR. Rituximab (monoclonal anti-CD20 antibody): Mechanisms of action and resistance. Oncogene. 2003;22:7359-68.
7. Edwards JCW, Szczepanski L, Szechinski J, Filipowicz-Sosnowska A, Emery P, et al. Efficacy of B-cell-targeted therapy with rituximab in patients with rheumatoid arthritis. New Engl J Med. 2004; 350:2572-81.
8. Cheung CM, Murray PI, Savage CO. Successful treatment of Wegener's granulomatosis associated scleritis with rituximab. Br J Ophthalmol. 2005;89:1542.
9. Ahmadi-Simab K, Lamprecht P, Nolle B, Ai M. Successful treatment of refractory anterior scleritis in primary Sjogren's syndrome with rituximab. Ann Rheum Dis. 2005;64:1087-8.
10. Kaushik VV, Reddy HV, BucknalR C. Successful use of rituximab in a patient with recalcitrant Churg-Strauss syndrome. Ann Rheum Dis. 2006;65:1116-7.
11. Eksioglu-Demiralp E, Kibaroglu A, Direskeneli H, et al. Phenotypic characteristics of B cells in Behçet's disease: Increased activity in B cell subsets. J Rheumatol. 1999;26:826-32.
12. Looney RJ, Anolik JH, Campbell D, Felgar RE, et al. B cell depletion as a novel treatment for systemic lupus erythematosus: A phase I/II dose-escalation trial of rituximab. Arthritis Rheum. 2004;50:2580-9.